Alerta

SCO-spondin-derived polypeptides for enhancing synaptic transmission

Resumen de: US2025177481A1

The invention relates to polypeptides derived from SCO-spondin for increasing or enhancing the basal excitatory synaptic transmission, notably glutamatergic neurotransmission. More particularly the invention relates to said polypeptides for increasing or enhancing glutamatergic neurotransmission in diseases or conditions comprising psychiatric disorders; drug addiction; viral infection (such as coronaviruses, e.g. SARS CoV2) related neurological symptoms; NMDA receptor (NMDAr) and/or AMPA receptor (AMPAr) deficiency related disease, notably anti-NMDAr encephalitis; vegetative state, and hypoxic brain injury. The present invention also relates to methods of treatment.

ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS

Resumen de: US2025177428A1

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

Method for Rapid Capture, Detection and Analysis of Viruses on Surfaces

Resumen de: US2025180560A1

Provided herein are, in various embodiments, methods and kits for assaying one or more virions. In certain embodiments, the methods and kits of the disclosure provide for the calculation of virion titer and/or virion infectivity. In still further embodiments, the disclosure provides for methods and kits for enhancing assaying of viruses such as SARS-CoV-2.

Real-Time Contactless Bio-Threat Screening

Resumen de: US2025180506A1

This present invention provides a system, method, and device for rapidly screening individuals at a high rate of speed. The invention features a method, system and device that analyzes an individual's body odors to determine the presence or absence of a disease such as COVID-19 and/or its variants. The invention allows for real-time testing for a pathogen, a disease, or other condition of interest that is especially useful when testing every individual entering or exiting a venue or transitioning through any controlled entry or exit zone demarcated by a portal, passage, security zone, or gate, etc. This testing requires no invasive sampling—or even touch contact—between the device or device operator and the person being tested. The device features a sensing surface whose electronic activity is a function volatile organic compounds (body odor) in the immediate vicinity of its surface.

Vaccine compositions for mucosal immune response

Resumen de: AU2025203389A1

Abstract A vaccine composition comprising a lyophilized, adenovirus-based expression vector encoding a disease antigen, and a stabilizing compound, such as aragonite. The disease antigen may comprise a viral protein or fragment thereof, such as a SARS-CoV2 virus protein. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.

MEASUREMENT OF NUCLEIC ACIDS IN A BIOLOGICAL SPECIMEN USING RT-LAMP

Resumen de: US2025179581A1

Methods and devices for utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP) to detect target DNA and RNA sequences for diagnostic and experimental assays, such as those for diagnosing and quantifying diseases, such as colorectal cancer and gastrointestinal disease, or pathogens, such as SARS-COV-2.

PEGYLATED SERP-1 PROTEIN TREATMENT IMPROVES OUTCOMES AFTER SARS-COV-2 INFECTION

Resumen de: US2025177541A1

Disclosed herein are methods of treating a lung disorder. In some embodiments, the lung disorder includes an acute respiratory syndrome. In some embodiments, the treatment includes administering to a subject in need thereof, a modified Serp-1 protein. The modified Serp-1 protein may include a therapeutic enhancing moiety. In some embodiments, the therapeutic enhancing moiety is a water soluble polymer such as polyethylene glycol.

ANTIVIRAL AGENTS FOR TREATMENT OF CORONAVIRUSES

Nº publicación: US2025177434A1 05/06/2025

Solicitante:

MEHARRY MEDICAL COLLEGE [US]
Meharry Medical College

Resumen de: US2025177434A1

An antiviral agent is provided, having a phosphorodiamidate morpholino oligomer with an antisense sequence to a portion of a genome of a strain of a coronavirus. The coronavirus may be SARS-CoV-2 or another βCoV. The antiviral agent finds many uses, such as in a pharmaceutical composition, a method of treating coronavirus-mediated disease, a method of preventing coronavirus-mediated disease, a method of reducing or preventing the replication of coronavirus in a host cell, a method of controlling the spread of coronavirus in donated tissue, a treated tissue sample, and in the manufacture of a medicament for the treatment or prevention or coronavirus-mediated disease.